Final Exam Pathophysiology Related

Review Final Exam Pathophysiology related questions and content

A patient is being educated about the use of raloxifene (Evista) for osteoporosis. What is the primary therapeutic action of this medication?

  • A. It stimulates the formation of new bone.
  • B. It decreases bone resorption and increases bone density.
  • C. It increases the excretion of calcium through the kidneys.
  • D. It increases calcium absorption in the intestines.
Correct Answer: B

Rationale: The correct answer is B: 'It decreases bone resorption and increases bone density.' Raloxifene, a selective estrogen receptor modulator (SERM), works by decreasing bone resorption, which is the breakdown of bone, and increasing bone density. This action helps in preventing bone loss and maintaining bone strength. Choice A is incorrect because raloxifene does not stimulate the formation of new bone but rather prevents its breakdown. Choice C is incorrect as raloxifene does not increase the excretion of calcium but rather helps in maintaining calcium levels in the bones. Choice D is also incorrect as raloxifene does not directly increase calcium absorption in the intestines.